A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

BACKGROUND: The phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is metabolised to hydroxylamine (PR-104H) and amine (PR-104M) DNA crosslinking agents by one-electron reductases in hypoxic cells and by aldo-keto reductase 1C3 independently o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: McKeage, Mark J, Gu, Yongchuan, Wilson, William R, Hill, Andrew, Amies, Karen, Melink, Teresa J, Jameson, Michael B
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3205073/
https://ncbi.nlm.nih.gov/pubmed/21982454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-432
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados